Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-03-18
2008-03-18
Hui, San-Ming (Department: 1617)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S587000
Reexamination Certificate
active
10153154
ABSTRACT:
The present invention provides a method for the long-term relief of chronic pain in a subject by activating in the subject an analgesic α-adrenergic receptor in the absence of α-2A receptor activation over a period of at least three days, such that relief of chronic pain is maintained in the absence of continued activation of said receptor. The analgesic α-adrenergic receptor can be, for example, the α-2B receptor.
REFERENCES:
patent: 5021410 (1991-06-01), Burke
patent: 6313172 (2001-11-01), Chow et al.
patent: 6329369 (2001-12-01), Chow et al.
patent: WO 99/28300 (1999-06-01), None
patent: WO 01/00586 (2001-01-01), None
patent: WO 01/78702 (2001-10-01), None
patent: WO 01/78703 (2001-10-01), None
Al-Chaer et al., “A new model of chronic visceral hypersensitivity in adult rats induced by colon irritation during postnatal development,”Gastroenterology119:1276-1285 (2000).
Altman et al., “Abnormal regulation of the sympathetic nervous system in α2-adrenergic receptor knockout mice,”Mol. Pharm. 56:154-161 (1999).
Beeley et al., “Synthesis of a selective alpha-2A adrenoceptor antagonist, BRL 48962, and its characterization at cloned human alpha-adrenoceptors,”Bioorganic&Med. Chem. 3:1693-1698 (1995).
Bennett and Xie, “A peripheral mononeuropathy in rat that produces disorders of pain sensation like those seen in man,”Pain33:87-107 (1988).
Boucher et al., “Potent analgesic effects of GDNF in neuropathic pain states,”Science290:124-127 (2000).
Bylund et al., “International Union of Pharmacology nomenclature of adrenoceptors,”Pharmacol. Rev., 46:121-136 (1994).
Calzada and Artiñano, “Alpha-adrenoceptor subtypes,”Pharm. Res. 44:195-208 (2001).
Conklin et al., “Substitution of three amino acids switches receptor specificity of Gq alpha to that of Gi alpha,”Nature363:274-276 (1993).
Dixon et al., “Efficient analysis of experimental observations,”Ann. Rev. Pharmacol. Toxicol. 20:441-462 (1980).
Dray, “Neurogenic mechanisms and neuropeptides in chronic pain,”Progress in Brain Res. 110:85-94 (1996).
Hein and Kobilka, “Adrenergic receptor signal transduction and regulation,”Neuropharmacol. 34:357-366 (1995).
Hein et al., “Gene substitution/knockout to delineate the role of α2-adrenoceptor subtypes in mediating central effects of catecholamines and imidazolines,”Ann. NY Acad. Science881:265-271 (1999).
Hieble et al., “α- and β-adrenoceptors: from the gene to the clinic. 1. Molecular biology and adrenoceptor subclassification,”J. Med. Chem. 38:3415-3444 (1995).
Kable et al., “In vivo gene modification elucidates subtype-specific functions of α2-adrenergic receptors,”J. Pharm. Exper. Ther. 293:1-7 (2000).
Kamibayashi and Maze, “Clinical uses of α2-adrenergic agonists,”Anesthesiology93:1345-1349 (2000).
Kim and Chung, “An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat,”Pain50:355-363 (1992).
Maze and Fujinaga, “α2adrenoceptors in pain modulation,”Anesthesiology92:934-936 (2000).
Messier et al., “High throughput assays of cloned adrenergic, muscarinic, neurokinin, and neurotrophin receptors in living mammalian cells,”Pharmacol. Toxicol. 76:308-311 (1995).
Minami et al., “Allodynia evoked by intrathecal administration of prostaglandin E2 to conscious mice,”Pain57:217-223 (1994).
Myers, “The pathogenesis of neuropathic pain,”Regional Anesthesia20:173-184 (1995) 1994 ASRA Lecture.
Roberts et al., “SK&F 104078, a post-junctionally selective α2-adrenoceptor antagonist in the human saphenous vein in vitro,”Arch. Pharmacol. 345:327-332 (1992).
Wang et al., “Antisense RNA/DNA-based techniques to probe adrenergic receptor function,”Meth. Mol. Biol. 126:241-258 (2000).
Woolf and Mannion, “Neuropathic pain: Aetiology, symptoms, mechanisms, and management,”The Lancet353:1959-1964 (1999).
Woolf and Salter, “Neuronal plasticity: Increasing the gain in pain,”Science288:1765-1768 (2000).
Yaksh, “Spinal systems and pain processing: Development of novel analgesic drugs with mechanistically defined models,”Trends Pharmacol. Science8:329-337 (1999).
Yaksh and Harty, “Pharmacology of the allodynia in rats evoked by high dose intrathecal morphine,”J. Pharmacology Exp. Ther. 244:501-507 (1988).
Young et al., “Novel α2-adrenoceptor antagonists show selectivity for α2A- and α2B-adrenoceptor subtypes,”Eur. J. of Pharmacol. 168:381-386 (1989).
Donello John E.
Gil Daniel W.
Allergan Inc.
Donovan Stephen
German Joel B.
Hui San-Ming
Voet Martin A.
LandOfFree
Methods and compositions for alleviating pain does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods and compositions for alleviating pain, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods and compositions for alleviating pain will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3926352